Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
Recruiting
Observational Study
Colorectal Cancer (Diagnosis)
Colorectal Liver Metastasis (CRLM)
Circulating Tumor DNA (ctDNA)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 21 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 35 (estimated)
- Sponsor
- Erasmus Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with colorectal liver metastases (CRLM).
The main question it aims to answer is:
* Can ctDNA be detected in small volumes of capillary blood collected using an automated samp…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 21 years
* A history of histologically confirmed (metastatic) colorectal adenocarcinoma
* Currently diagnosed with (progressive) colorectal liver metastases (CRLM)
* Signed informed consent
Exclusion Criteria:
* Patients who are treated and having a response on chemoth…
Contacts